POLB001 CRS Patent Granted in South Korea

Poolbeg Pharma PLC

06 October 2026

 

Poolbeg Pharma plc

Cancer Immunotherapy-Induced CRS Patent Granted in South Korea
Patent grant further strengthens POLB 001’s global intellectual property portfolio

6 October 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that a South Korean patent relating to POLB 001 has been formally granted. The patent, entitled "Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome", provides protection for POLB 001 and the use of any p38 MAP kinase inhibitor for the prevention of cancer immunotherapy-associated Cytokine Release Syndrome ("CRS") in South Korea with a default expiry of 2044.

POLB 001 is a potent and selective p38 MAP kinase inhibitor being developed as a potential preventative treatment for cancer immunotherapy-associated CRS. CRS is a recognised and potentially serious complication associated with a range of cancer immunotherapies and represents a significant unmet medical need.

The South Korean patent grant further strengthens Poolbeg's growing international intellectual property portfolio for POLB 001, particularly in the strategically important area of cancer immunotherapy-associated CRS. Poolbeg has continued to expand its patent estate around POLB 001 through granted patents, including Europe, Canada and Australia, and patent applications covering multiple therapeutic applications and territories. Developing a robust global intellectual property portfolio remains a key priority for the Company, enhancing POLB 001's value and attractiveness to prospective pharmaceutical partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "This latest patent grant for South Korea adds to our growing international cancer immunotherapy-associated CRS patent estate, enhancing POLB 001's attractiveness to prospective partners, and reflects the continued momentum we are generating across the programme.”

Enquiries 

Poolbeg Pharma Plc   Jeremy Skillington, CEO   Ian O'Connell, CFO	[phone]  [e-mail]
Cavendish Capital Markets Ltd (NOMAD & Joint Broker)   Geoff Nash, Trisyia Jamaludin (Corporate Finance)  Nigel Birks (Life Science Specialist Sales)  Harriet Ward (ECM)	[phone]
Shore Capital Stockbrokers Ltd (Joint Broker)  David Coaten, Harry Davies-Ball (Corporate Advisory)  Malachy McEntyre (Corporate Broking)	[phone]
J&E Davy (Joint Broker)   Anthony Farrell, Niall Gilchrist	[phone]
Optimum Strategic Communications   Nick Bastin, Katie Flint, Henry Williams	[phone]   [e-mail]

About Poolbeg Pharma plc 

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

END